Vertex Pharmaceuticals Inc (VRTX.O): Crinetics acquisition brings a new endocrine pillar that fits the playbook

Research evidence excerpt

Vertex Pharmaceuticals Inc (VRTX.O): Crinetics acquisition brings a new endocrine pillar that fits the playbook

Flash |

06 Jul 2026 18:29:14 ET │ 11 pages

Vertex Pharmaceuticals Inc (VRTX.O)

Crinetics acquisition brings a new endocrine pillar that fits the playbook

CITI'S TAKE

Buy Vertex’s Crinetics acquisition (announced today) is a clean rare-endocrine

pipeline-and-commercial build, in our view, adding a launched Price (06 Jul 26 16:00) US$529.59

acromegaly asset and late-stage CAH/ADCS optionality rather than Target price US$585.00

changing the strategic narrative. The $85/sh cash price values Crinetics at Expected share price return 10.5%

a ~100% premium to today’s close ($10B equity value), which looks Expected dividend yield 0.0%

defendable given Palsonify’s de-risked launch as the first once-daily oral Expected total return 10.5%

therapy for adults with acromegaly and atumelnant’s potential to

Market Cap US$134,413M normalize A4 while maintaining physiologic glucocorticoid dosing in phase

3 for adults with CAH. We think the fit is clear, given existing expertise

(from CF) in specialty markets, serious diseases, causal biology, and

measurable biomarkers. The >$5B peak sales framing adds another route Geoff Meacham, Ph.D.AC

to sustain double-digit topline growth beyond CF, with endocrine joining +1-404-443-4701

kidney, heme, and pain as emerging pillars. Both boards unanimously geoffrey.meacham@citi.com

approved the deal, with closing expected in 3Q26. Maintain Buy and $585

Jarwei Fang

TP.

+1-212-816-5127

jarwei.fang@citi.com

Deal fits the wheelhouse — We view Crinetics as a natural extension of Vertex’s

Nishant Gandhi, Ph.D.

operating model: rare specialty markets, serious diseases, known biology, validated

nishant.gandhi@citi.com